BioSpace News Archive

BioSig Technologies, Inc., a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.

LianBio (NASDAQ: LIAN) today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs (the “Proposal”).

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET.

Modernizing the 150-year-old microscope-based practice with digital innovation

Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.

Medical technology innovator Thornhill Medical is pleased to announce that the United States Marine Corps (USMC) has acquired its integrated life support technology, MOVES® SLC™.

Researchers at the University of Central Florida College of Medicine (UCF COM) in Orlando, Florida completed research that is very promising in the treatment of Parkinson’s disease.

Teva Pharmaceutical Industries Ltd. announces that a post hoc analysis4 of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® in reducing migraine attacks in patients with migraine and co-morbid obesity.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, December 6, 2023.

Coherus BioSciences, Inc., announced data from the ongoing Phase 1b/2 clinical trial of casdozokitug, a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress taking place December 6 – 8, 2023 at Palexpo Exhibition Centre in Geneva, Switzerland.